Search Results 1-20 of 57

  • 1 / 3
  • Systemic therapy for advanced hepatocellular carcinoma in Japan  [in Japanese]

    土谷 薫 , 金子 俊 , 桐野 桜 , 王 婉 , 早川 優香 , 安井 豊 , 黒崎 雅之 , 泉 並木

    腫瘍内科 = Clinical oncology 25(2), 108-116, 2020-02

    Ichushi Web 

  • Outcomes of Refractory Metastatic Colorectal Cancer Patients Treated with Regorafenib and Trifluridine / Tipiracil as Late Line Treatment  [in Japanese]

    Chikatani Kenichi , Ishida Hideyuki , Ishibashi Keiichiro , Chika Noriyasu , Hatano Satoshi , Amano Kunihiko , Ishiguro Tohru , Fukuchi Minoru , Kumagai Youichi , Mochiki Erito

    … 象・方法】2013年7月~2016年12月の間にlate lineとしてregorafenib,trifluridine / tipiracil(TFTD)の少なくとも1剤を使用した切除不能進行再発大腸癌41例を対象に,診療録からデータを抽出し,後方視的に解析した.【結果】Regorafenib先行群25例,TFTD先行群16例の間で無増悪生存期間,全生存期間ともに有意差を認めなかった.RegorafenibまたはTFTDのみが使用された22例より,2剤が使用さ …

    Nihon Gekakei Rengo Gakkaishi (Journal of Japanese College of Surgeons) 44(2), 167-175, 2019

    J-STAGE  Ichushi Web 

  • Successful Treatment of Hepatocellular Carcinoma with Regorafenib after Sorafenib-induced Hypersensitivity

    Yoshioka Naoki , Kuzuya Teiji , Ito Takanori , Ishizu Yoji , Honda Takashi , Ishikawa Tetsuya , Ishigami Masatoshi , Fujishiro Mitsuhiro

    … <p>Sorafenib and regorafenib are tyrosine kinase inhibitors that are used in the treatment of hepatocellular carcinoma and which have similar chemical structures and toxicity profiles. … We herein report a case in which regorafenib treatment could be continued for 10 months and stable disease could be maintained for a long period despite the discontinuation of sorafenib due to grade 4 liver injury and grade 3 fever. … A DLST for regorafenib was negative. …

    Internal Medicine 58(19), 2803-2808, 2019

    J-STAGE 

  • Gastrointestinal Stromal Tumor in a Patient with Neurofibromatosis Type 1 That Was Successfully Treated with Regorafenib

    Fujimi Akihito , Takada Kohichi , Kobayashi Ko , Kato Junji , Nagamachi Yasuhiro , Yamauchi Naofumi , Tamura Fumito , Kimura Tomohiro , Miyajima Naoya , Inomata Hidetoshi , Nishisato Takuji , Yoshida Makoto

    … After six cycles of regorafenib therapy, <sup>18</sup>F-fluorodeoxyglucose accumulation in the duodenal GIST on positron emission tomography-computed tomography (PET-CT) showed a partial metabolic response. … Regorafenib may thus be considered as and appropriate initial therapy. …

    Internal Medicine 58(13), 1865-1870, 2019

    J-STAGE  Ichushi Web 

  • 消化器がん  [in Japanese]

    岡崎 聡 , 植竹 宏之

    … 消化器がん領域では, 主に, ① 上皮成長因子受容体阻害薬 (EGFR 阻害薬: Cetuximab, Panitumumab, Erlotinib) や ② 血管新生阻害薬 (VEGF 阻害薬: Bevacizumab, Ramucirumab, Aflibercept beta) のほか, ③ 腫瘍の増殖・進展に関連する複数の分子を阻害するマルチキナーゼ阻害薬 (Sorafenib, Imatinib, Sunitinib, Regorafenib) などが用いられている. …

    Nippon Jibiinkoka Gakkai Kaiho 122(5), 717-723, 2019

    J-STAGE  Ichushi Web 

  • Study Protocol of Regorafenib Escalation for Colorectal Cancer (RECC): A Phase II Multicenter Clinical Trial of the Efficacy and Safety of Regorafenib Dose Escalation Therapy as the Third or Fourth Line Therapy for Unresectable/Recurrent Colorectal Cancer

    SUGIMOTO KIICHI , OCHIAI TAKUMI , SONODA HIROMICHI , TANI MASAJI , ENOMOTO MASANOBU , KATSUMATA KENJI , YAMAGUCHI TATSURO , OHTA RYO , ISHIMARU KEI , WATANABE YUJI , KODA KEIJI , YAMADA TAKESHI , SAKAMOTO KAZUHIRO , ISHIYAMA SHUN , NAKAMURA MASATO , YOSHIDA YOICHIRO , HASEGAWA SUGURU , YOKOMIZO HAJIME , NARITAKA YOSHIHIKO , SAKUYAMA NAOKI

    Regorafenib (BAY 73-4506) is an oral multikinase inhibitor that has been shown to inhibit various oncogenic stromal receptor tyrosine kinases and intracellular signaling kinase. … The aim of the study is to confirm the safety and effectiveness of dose escalation therapy of regorafenib for the third- or fourth- treatments of patients with unresectable and recurrent colorectal cancer.</p><p><b><i>Design:</i></b> …

    Juntendo Medical Journal 65(1), 85-91, 2019

    J-STAGE  Ichushi Web 

  • A Case of Incomplete-type Carney's Triad With Stomach GIST Resistant to Tyrosine Kinase Inhibitors  [in Japanese]

    Samejima Yoshitomo , Maeda Kosaku , Fukuzawa Hiroaki , Kawahara Insu , Kajihara Keisuke , Isono Kaori , Murakami Shizu , Morita Keiichi , Nakao Makoto , Yokoi Akiko

    <p>胃GIST,肺軟骨腫,副腎外神経節腫の3病変を伴う稀な疾患をCarney's triadと呼び,若年女性に多いことが知られている.通常のGIST発生機序と異なり,コハク酸脱水素酵素(SDH)機能異常が原因となる.今回,胃と肺の2病変を伴う不完全型Carney's triadを経験したので報告する.症例は19歳女性.10歳時に胃前庭部の粘膜下腫瘍と多発肺腫瘤を認め,胃部分切除術を施 …

    Journal of the Japanese Society of Pediatric Surgeons 55(1), 104-109, 2019

    J-STAGE  Ichushi Web 

  • Regorafenib in patients with advanced hepatocellular carcinoma;current status and future perspective  [in Japanese]

    OGASAWARA Sadahisa , OOKA Yoshihiko , KATO Naoya

    <p>進行肝細胞癌においてソラフェニブの有効性が示されて以降,複数の有望な化合物の開発治験が不成功に終わった.ほぼ10年間の"進行肝細胞癌に対する薬物治療開発の不毛時代"の後,進行肝細胞癌に対する2剤目の有効性を示したチロシンキナーゼ阻害薬がレゴラフェニブである.適正使用の啓蒙により,当初懸念されていた有害事象のマネージメントも難渋することは多くない.進行肝細胞癌において複数のチロシン …

    Nippon Shokakibyo Gakkai Zasshi 116(1), 28-35, 2019

    J-STAGE  Ichushi Web 

  • A Case of Acute Pancreatitis Induced by Regorafenib  [in Japanese]

    近藤 有 , 堀 貴洋 , 横山 尚美 , 榊原 崇芳 , 加藤 潤 , 平岩 いずみ , 酒井 幹康 , 森田 清

    日本病院薬剤師会雑誌 = Journal of Japanese Society of Hospital Pharmacists 54(12), 1483-1487, 2018-12

    Ichushi Web 

  • Propensity Score Analysis of Regorafenib Versus Trifluridine/Tipiracil in Patients with Metastatic Colorectal Cancer Refractory to Standard Chemotherapy (REGOTAS): A Japanese Society for Cancer of the Colon and Rectum Multicenter Observational Study

    Moriwaki Toshikazu , Fukuoka Shota , Taniguchi Hiroya , Takashima Atsuo , Kumekawa Yusuke , Kajiwara Takeshi , Yamazaki Kentaro , Esaki Taito , Makiyama Chinatsu , Denda Tadamichi , Satake Hironaga , Suto Takeshi , Sugimoto Naotoshi , Enomoto Masanobu , Ishikawa Toshiaki , Kashiwada Tomomi , Sugiyama Masahiko , Komatsu Yoshito , Okuyama Hiroyuki , Baba Eishi , Sakai Daisuke , Watanabe Tomoki , Tamura Takao , Yamashita Kimihiro , Gosho Masahiko , Shimada Yasuhiro , 森脇 俊和 , 五所 正彦

    … Background.This study compared the efficacy of regorafenib and trifluridine/tipiracil (TFTD) in patients with metastatic colorectal cancer (mCRC) who are refractory to standard chemotherapy, because despite their clinical approval, it still remains unclear which of these two drugs should be used as initial treatment.Materials and Methods.The clinical data of patients with mCRC who were treated with regorafenib or TFTD and those of drug‐naive patients, between June 2014 and September 2015, were retrospectively collected from 24 …

    The oncologist 23(1), 7-15, 2018-11

    IR 

  • Sarcoma of gastrointestinal tract  [in Japanese]

    内藤 陽一 , 土井 俊彦

    外科 = Surgery : 臨床雑誌 80(4), 330-335, 2018-04

    Ichushi Web 

  • How does the second-line systemic therapy for advanced hepatocellular carcinoma change? : Positioning of regorafenib  [in Japanese]

    山下 竜也 , 荒井 邦明 , 金子 周一

    腫瘍内科 = Clinical oncology 21(3), 254-261, 2018-03

    Ichushi Web 

  • Evidence-based recommendation for lenvatinib in patients with advanced hepatocellular carcinoma  [in Japanese]

    小笠原 定久 , 鈴木 英一郎 , 大岡 美彦 , 千葉 哲博 , 加藤 直也

    腫瘍内科 = Clinical oncology 21(3), 249-253, 2018-03

    Ichushi Web 

  • Molecular targeted agents  [in Japanese]

    池田 公史

    日本臨床 = Japanese journal of clinical medicine 76(2), 259-266, 2018-02

    Ichushi Web 

  • Health-related quality of life associated with regorafenib treatment in refractory advanced gastric adenocarcinoma

    Martin Andrew J. , Gibbs Emma , Sjoquist Katrin , Pavlakis Nick , Simes John , Price Tim , Shannon Jenny , Gill Sanjeev , Jain Vikram , Liu Geoffrey , Kannourakis George , Kim Yeul Hong , Kim Jin Won , Goldstein David

    Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association 21(3), 473-480, 2018

    Ichushi Web 

  • Surgical Management of Regorafenib-tolerant Progressing Metastatic Gastrointestinal Stromal Tumor—Report of a Case—  [in Japanese]

    SAKANO Yoshihiro , SAITO Takuro , KISHI Kentaro , MASUZAWA Toru , HIROTA Seiichi , AKAMATSU Hiroki

    72歳,女性.前医で胃GISTに対して胃部分切除術が施行され,術後6カ月間イマチニブが投与された.術後3年目に肝転移・多発腹膜播種再発を認めたが,イマチニブを再開し無増悪で経過していた.術後6年目のCTで胃背側および傍下行結腸に新規腹膜播種病変を認めた.この腹膜播種2病変は,スニチニブの投与で一旦縮小を示すも再増大したためレゴラフェニブを投与したが,さらに増大傾向を示した.この2病変のみ,PET- …

    Nihon Rinsho Geka Gakkai Zasshi (Journal of Japan Surgical Association) 79(10), 2053-2057, 2018

    J-STAGE  Ichushi Web 

  • Systemic Therapy for Hepatocellular Carcinoma: Recent Advances  [in Japanese]

    Kudo Masatoshi

    <p>2007年に分子標的薬ソラフェニブがSHARP試験とAsia Pacific試験において肝細胞癌に対する予後延長効果が示されて以来,肝細胞癌の薬物療法は大きく変化した.遠隔転移,脈管浸潤に対する治療選択肢が増え,進行性肝癌でもある程度長期生存が得られるようになったが,ソラフェニブは腫瘍縮小効果が乏しいことや手足症候群などの比較的強い副作用から,ソラフェニブに代わる新規分子標的薬や …

    Kanzo 59(11), 587-603, 2018

    J-STAGE 

  • A Case of Sigmoid Colon Cancer with Hepatic Metastases and Jaundice Treated with Rechallenge of Anti-epidermal Growth Factor Receptors as Fifth-line Treatment  [in Japanese]

    AGATSUMA Yuya , IIZUKA Akimitsu , NAKAMURA Shunsuke , ISHIYAMA Akiharu , MORI Toshiaki , YOKOI Kazuki

    症例は62歳,男性.S状結腸癌,多発肝転移.KRAS は野生型.化学療法としてPmab+FOLFOX療法,Bmab+FOLFIRI療法TAS-102,レゴラフェニブを使用したがすべて不応の判断.T-Bil16.3mg/dlであったがPS0かつ患者本人および妻より化学療法継続の強い意志が示されたため十分なICの上,Cmab単剤投与を開始.4コース施行したところでT-Bil2.1mg/dlと改善しS- …

    Nihon Rinsho Geka Gakkai Zasshi (Journal of Japan Surgical Association) 79(4), 849-853, 2018

    J-STAGE  Ichushi Web 

  • A Case of Thrombotic Microangiopathy Associated with Lenvatinib for Hepatocellular Carcinoma  [in Japanese]

    高橋 将典 , 薄井 健介 , 岡田 浩司 , 小暮 高之 , 佐藤 賢一 , 中村 仁 , 村井 ユリ子 , 渡辺 善照

    … only 3 anti-vascular endothelial growth factor receptor(VEGFR)drugs, sorafenib, regorafenib and lenvatinib, are available for HCC therapy. …

    東北医科薬科大学研究誌 = Journal of Tohoku Medical and Pharmaceutical University (65), 55-61, 2018

    IR  Ichushi Web 

  • New molecular targeted agents for hepatocellular carcinoma : Evidence of regorafenib and lenvatinib  [in Japanese]

    池田 公史

    腫瘍内科 = Clinical oncology 20(6), 646-652, 2017-12

    Ichushi Web 

  • 1 / 3
Page Top